AKT1 and ovarian carcinoma: Preclinical studies have demonstrated that TCM and its active constituents can inhibit the proliferation of ovarian cancer cells, promote apoptosis, reverse drug resistance, and modulate key oncogenic signaling pathways, including PI3K/Akt/mTOR, Wnt/β-catenin, Notch, NF-κB, and MAPK pathways (24–28).